Kidney organoid differentiation
Directed differentiation workflows for generating human nephron-like organoids from pluripotent stem cells.
Innovation and Translation
Turning human kidney models into translational platforms.
Technologies developed by the Morizane Lab have contributed to patented inventions and translational platforms for human kidney disease modeling, therapeutic evaluation, kidney safety research, and regenerative medicine.
Translation strategy
Bridging stem cell biology, kidney medicine, bioengineering, imaging, and therapeutic discovery
Our work connects human iPSC-derived kidney organoids, patient-derived disease models, vascularized organoids, organ-on-chip systems, AI-assisted 3D imaging, and molecular profiling. The goal is to build human-relevant systems that can support disease mechanism studies, target validation, therapeutic evaluation, and kidney safety research.
Institutional pathway
Technology development, sponsored research, material transfer, and licensing discussions should proceed through appropriate Mass General Brigham institutional channels.
Translational platforms
Innovation areas
Patient-derived disease modeling
iPSC-derived kidney organoids that carry disease-relevant genetic backgrounds for mechanism studies and therapeutic evaluation.
Vascularized kidney tissues
Methods for advancing vascularized kidney organoid systems and scalable tissue production.
Perfusable organoid-on-chip systems
Microphysiological systems designed to incorporate flow, tubular function, and kidney-relevant physical cues.
AI-assisted 3D phenotyping
Automated imaging and analysis pipelines for quantitative organoid phenotyping and high-content screening.
Gene therapy kidney response models
Human kidney organoid systems to study AAV-associated kidney response and gene therapy safety questions.
Patent and licensing placeholders
Technologies to confirm with institutional offices before publication
These entries are based on the local CV text and should be reviewed with the Mass General Brigham innovation or licensing office before public use, especially if patent titles, application numbers, or licensing contacts change.
Methods and compositions for use in treating ARPKD
PCT/US23/71029, July 26, 2023. Related to therapeutic applications for autosomal recessive polycystic kidney disease.
Perfusable 3D tubule-on-chip model derived from kidney organoids
PCT/US23/73271, September 1, 2023. Related to perfusable tubular chip models using proximal tubular cells derived from human kidney organoids.
Mass production method of vascularized kidney tissue
Provisional filing, October 2025. Related to scalable production of vascularized kidney organoids.
Gene therapy for ARPKD by epigenome editing
Provisional filing, February 2026. Related to a new therapeutic approach for ARPKD.
From platform to partnership
Collaborate on translational kidney questions.
We welcome sponsored research and collaborative research through appropriate institutional agreements. Potential areas include kidney organoid disease modeling, nephrotoxicity organoid models, AAV kidney toxicity, gene therapy kidney safety, organ-on-chip systems, and AI imaging kidney organoids.